Pharmacokinetic-pharmacodynamic modeling:: Why?

被引:41
作者
Pérez-Urizar, J
Granados-Soto, V
Flores-Murrieta, FJ
Castañeda-Hernández, G
机构
[1] CINVESTAV, IPN, Ctr Invest & Estudios Avanzados, Dept Farmacol & Toxicol, Mexico City 14000, DF, Mexico
[2] IPN, Escuela Super Med, Secc Graduados, Mexico City 07738, DF, Mexico
关键词
PK-PD modeling; pharmacokinetics; pharmacodynamics; data analysis;
D O I
10.1016/S0188-4409(00)00242-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
At present, pharmacokinetic-pharmacodynamic (PK-PD) modeling has emerged as a major tool in clinical phamacology to optimize drug use by designing rational dosage forms and dosage regimes. Quantitative representation of the dose-concentration-response relationship should provide information for prediction of the level of response to a certain level of drug dose. Several mathematical approaches can be used to describe such relationships, depending on the single dose or the steady-state measurements carried out. With concentration and response data on-phase, basic models such as fixed-effect, linear, log-linear, E-MAX, and sigmoid E-MAX can be sufficient. However, time-variant pharmacodynamic models (effect compartment, acute tolerance, sensitization, and indirect responses) can be required when kinetics and response are out-of-phase. To date, methodologies available for PK-PD analysis barely suppose the use of powerful computing resources. Some of these algorithms are able to generate individual estimates of parameters based on population analysis and Bayesian forecasting. Notwithstanding, attention must be paid to avoid overinterpreted data from mathematical models, so that reliability and clinical significance of estimated parameters will be valuable when underlying physiologic processes (disease, age, gender, etc.) are considered. (C) 2001 IMSS. Published by Elsevier Science Inc.
引用
收藏
页码:539 / 545
页数:7
相关论文
共 56 条
[1]   Software for population pharmacokinetics and pharmacodynamics [J].
Aarons, L .
CLINICAL PHARMACOKINETICS, 1999, 36 (04) :255-264
[2]  
AARONS L, 1997, PHARMACOKINETIC PHAR
[3]   MOLECULAR BASIS FOR DRUG ACTION [J].
ARIENS, EJ ;
SIMONIS, AM .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1964, 16 (03) :137-&
[4]  
Balant LP, 1996, THERAPIE, V51, P390
[5]   Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure [J].
Bauer, JA ;
Balthasar, JP ;
Fung, HL .
PHARMACEUTICAL RESEARCH, 1997, 14 (09) :1140-1145
[6]   Methodological issues in pharmacokinetic-pharmacodynamic modelling [J].
Bellissant, E ;
Sébille, V ;
Paintaud, G .
CLINICAL PHARMACOKINETICS, 1998, 35 (02) :151-166
[7]   Efficacy measures: Surrogates or clinical outcomes? [J].
Blue, JW ;
Colburn, WA .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (09) :767-770
[8]  
BOECKMANN AJ, 1994, NONMEM USERS GUIDE 5, P32
[9]   FIRST-TIME-IN-HUMAN DOSE SELECTION - ALLOMETRIC THOUGHTS AND PERSPECTIVES [J].
BOXENBAUM, H ;
DILEA, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (10) :957-966
[10]   Integrated pharmacokinetic-pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children [J].
Brown, RD ;
Kearns, GL ;
Wilson, JT .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1998, 26 (05) :559-579